Back to Journals » OncoTargets and Therapy » Volume 9

Successful treatment of advanced malignant fibrous histiocytoma of the right forearm with apatinib: a case report

Authors Ji G, Hong L, Yang P

Received 10 September 2015

Accepted for publication 21 December 2015

Published 5 February 2016 Volume 2016:9 Pages 643—647


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Manfred Beleut

Peer reviewer comments 3

Editor who approved publication: Professor Daniele Santini

Guanghui Ji,1 Liu Hong,2 Ping Yang3

1Department of Traditional Chinese Medicine, 2Department of Pathology, 3Department of Oncology, Navy General Hospital, Beijing, People’s Republic of China

Abstract: Malignant fibrous histiocytoma (MFH) is the most common soft-tissue sarcoma in late adult life. Unfortunately, advanced MFH has a poor prognosis due to a lack of effective drugs. We present here a case of advanced MFH with partial response to apatinib, a new potent oral small-molecule tyrosine kinase inhibitor targeting the intracellular domain of vascular endothelial growth factor receptor 2 (VEGFR-2). To the best of our knowledge, this is the first case report using apatinib for MFH. Quantitative polymerase chain reaction analysis revealed high expression of VEGFR-2 mRNA, suggesting that apatinib leads to clinical response by inhibiting VEGFR-2 tyrosine kinase activity and the crucial role of VEGFR-2 for MFH. Apatinib could be a new option for the treatment of MFH. Further studies are needed to optimize the treatment.

Keywords: malignant fibrous histiocytoma, apatinib, chemotherapy, angiogenesis inhibitor, targeted therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]